logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10370452 B1

PDFFull Text
Date of Patent:
Aug. 06, 2019

Filed:

Oct. 02, 2015

Effective generation of tumor-targeted t cells derived from pluripotent stem cells

Applicant:

Memorial Sloan-kettering Cancer Center, New York, NY (US);

Inventors:

Maria Themeli, New York, NY (US);

Michel Sadelain, New York, NY (US);

Christopher C. Kloss, New York, NY (US);

Assignee:

MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US);

Attorney:

Baker Botts L.L.P.

Primary Examiner:

Peter J Reddig

Int. Cl.
CPC ...
A61K 35/12 (2015.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 16/30 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); C07K 14/47 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/2803 (2013.01); C12N 5/0638 (2013.01); C12N 5/0646 (2013.01); A61K 2035/124 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/70 (2013.01); C07K 2319/74 (2013.01); C12N 2506/45 (2013.01); C12N 2510/00 (2013.01); C12N 2740/13043 (2013.01); C12N 2740/16043 (2013.01);
Abstract

The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and/or expandable T cells from pluripotent stem cells engineered through safe genetic modifications. The engineered cells may provide one or more of: 1) targeting a specific predetermined antigen expressed on the cell surface of a target cell in an HLA independent manner, 2) enhanced survival and functional potential 3) 'off-the-shelf' T cells for administration to multiple recipients, eventually across immunogenic barriers, and/or 4) cytotoxic potential and anti-tumor activity.

Find Patent Forward Citations

Loading…